Navigation Links
Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an
Date:5/23/2013

TOKIO, 22. Mai 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (im Weiteren Ranbaxy), eine Tochtergesellschaft von Daiichi Sankyo Co., Ltd. (im Weiteren Daiichi Sankyo), gab am 22. Mai die Maßnahmen bekannt, die Ranbaxy in den letzten Jahren ergriffen hat, um sich der Angelegenheiten der vorhergehenden Unternehmensführung anzunehmen.

(http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).

Daiichi Sankyo unterstützt Ranbaxy weiterhin dabei, die Fehler der vorhergehenden Geschäftsführung zu korrigieren, welche zu Untersuchungen durch das Justizministerium der Vereinigten Staaten und die US-Arzneimittelzulassungsbehörde („USFDA") geführt hatten. Die Änderungen, die bei Ranbaxy vorgenommen werden sollen, umfassen die Geschäftsführung, die Unternehmenskultur, den Betrieb und die Compliance.

Daiichi Sankyo geht davon aus, dass bestimmte ehemalige Aktionäre von Ranbaxy wichtige Informationen hinsichtlich der Untersuchungen durch das US-Justizministerium und die FDA verschwiegen und falsch dargestellt haben. Daiichi Sankyo prüft derzeit die verfügbaren Rechtsmittel und kann das Thema nicht weiter kommentieren.

Informationen zu Daiichi Sankyo Co., Ltd. 
Börsennotierung: Börsenkürzel: 4568, Erster Index der Börsen in Tokio, Osaka und Nagoya
Präsident und CEO: Joji Nakayama

Kontakt: 
Noriaki Ishida 
Corporate Officer & Vice President 
Abteilung für Unternehmenskommunikation
Daiichi Sankyo Co., Ltd. 
Tel.: +81-3-6225-1126 
E-Mail: kondo.toshiya.cj@daiichisankyo.co.jp

http://www.daiichisankyo.com/


'/>"/>
SOURCE Daiichi Sankyo Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
3. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
4. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
5. Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.
6. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
7. Statement By Dinesh Thakur Regarding US Governments Case Against Ranbaxy
8. Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
9. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
10. Simbionix kündigt Lizenzvertrag für chirurgische Videos an
11. Blue Belt Technologies kündigt Gründung eines wissenschaftlichen Beirats für Hüfteingriffe zur Bestimmung neuer Anwendungsgebiete von NavioPFS bei femoro-acetabulärem Impingement an
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):